Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Real-time Estimate Cboe BZX Other stock markets 10:02:45 2024-06-03 am EDT			5-day change	1st Jan Change
39.65 ^USD	-0.85%		+4.74%	+54.40%

May. 31	Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39	MT
May. 31	Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	May. 30	AQ
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders	May. 28	BU
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress	May. 28	AQ
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation	May. 28	AQ
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)	May. 23	PU
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Report)	May. 23	PU
Calliditas Q1 report, January - March 2024	May. 23	AQ
In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024	May. 16	PU
Invitation to the presentation of Calliditas's interim report January - March 2024	May. 16	AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm	May. 15	AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)	May. 15	AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	May. 14	AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	May. 06	AQ
Calliditas Therapeutics' 2023 Annual Report Published	Apr. 24	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	Apr. 24	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	AQ
Calliditas Therapeutics to Attend Conferences in April	Apr. 09	AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires	Apr. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Press Releases

Filters